GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Lords Mark Industries Ltd

Lords Mark Industries Reports Revised Q2 FY27 Net Profit of ₹4,739.78 Lakhs

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 14 Nov 2026, 10:58 PM IST  ·  BSE ID: aba4b189-c441-4b91-bb44-09f6584b300f
View Original BSE Filing (PDF)
💡
In Simple Terms
The company revised its financial report, showing a net profit of ₹4,739.78 Lakhs for the quarter, along with business updates.
🤖 AI Summary
  • Lords Mark Industries submitted revised unaudited financial results for Q2 FY27 and Half Year ended September 30, 2026.
  • Revised standalone net profit for Q2 FY27 stands at ₹4,739.78 Lakhs.
  • Revised standalone revenue from operations for the half year ended September 30, 2026, is ₹65,530.62 Lakhs.
  • Consolidated net profit for the half year ended September 30, 2026, is ₹8,201 Lakhs.
  • Management highlighted operational advancements including 26 new medical device licenses and AI-based product launches.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Standalone Revenue from Operations (6 Months Ended 30/09/2026)
65,530.62 Lakhs
Not comparable — limited prior period data.
Standalone Net Profit (Quarter Ended 30/09/2026)
4,739.78 Lakhs
Not comparable — limited prior period data.
Standalone Net Profit (6 Months Ended 30/09/2026)
7,956.22 Lakhs
Not comparable — limited prior period data.
Consolidated Revenue (6 Months Ended 30/09/2026)
71,877 Lakhs
Consolidated PAT (6 Months Ended 30/09/2026)
8,201 Lakhs
🏢 How This Affects the Company
📈
Business Impact
The medical device division witnessed a significant increase in sales and profitability, supported by 26 additional manufacturing licenses. New product launches like AI-based dialysis machines and breast cancer screening devices are scheduled.
💰
Financial Impact
The revised standalone net profit for Q2 FY27 is ₹4,739.78 Lakhs. Half-year standalone revenue from operations is ₹65,530.62 Lakhs, with PBT of ₹10,864.70 Lakhs.
⚙️
Operational Impact
Production of AI-based dialysis machines has commenced at the Bangalore facility. The company is establishing a US subsidiary, Lords Mark Industries Inc., and a UK subsidiary has secured MHRA approvals for operations.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this financial results submission.
👤
Who Is Affected
All shareholders are affected by the revised financial performance, with the company reporting a standalone net profit of ₹4,739.78 Lakhs for Q2 FY27. Basic EPS is ₹1.11.
🔍
Management Signal
The management's decision to revise financial results and provide comprehensive operational updates signals a commitment to transparency and business expansion.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 results — monitor impact of new product launches and global shipments.
Launch of Sickle Cell screening product in January 2027.
Commencement of CAR-T therapy clinical trials in February 2027.
LOW RISK The filing reports positive revised financials and outlines strategic growth initiatives with specific timelines.
💡 Investor Takeaway
Lords Mark Industries reported a revised standalone net profit of ₹4,739.78 Lakhs for Q2 FY27. Standalone revenue from operations for the half year ended September 30, 2026, reached ₹65,530.62 Lakhs. The company is expanding its medical device division and global presence.
⚖️ Strengths & Concerns

✅ Positives

  • Standalone net profit for Q2 FY27 is ₹4,739.78 Lakhs, indicating profitability for the quarter.
  • Secured 26 additional licenses for medical device manufacturing, expanding production capacity and market reach.

⚠️ Concerns

  • Prior period financial data for Q2 FY26 showed a net loss of ₹242.01 Lakhs, limiting direct comparable growth metrics.
  • Several key product launches and operational expansions are scheduled for future months (January-March 2027), yet to contribute to current financials.
📅 Company Track Record
Previous filings indicated Lords Mark Industries reported an initial Q2 FY27 net profit of Rs. 1,582.80 Lakhs, which has now been revised to Rs. 4,739.78 Lakhs. The prior year Q2 FY26 showed a standalone net loss of (₹242.01) Lakhs, with the company showing significant growth in its subsequent full year ended March 31, 2026, reporting a net profit of ₹5,276.08 Lakhs.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What is the revised standalone net profit for Lords Mark Industries in Q2 FY27?
The revised standalone net profit for Lords Mark Industries for the quarter ended September 30, 2026 (Q2 FY27) is ₹4,739.78 Lakhs.
What is the standalone revenue from operations for Lords Mark Industries for the half year ended September 30, 2026?
The standalone revenue from operations for the half year ended September 30, 2026, is ₹65,530.62 Lakhs.
What is the consolidated net profit reported by Lords Mark Industries for the half year ended September 30, 2026?
The consolidated net profit for Lords Mark Industries for the half year ended September 30, 2026, is ₹8,201 Lakhs.
What new manufacturing licenses has Lords Mark Industries secured?
Lords Mark Industries has successfully secured 26 additional licenses for medical device manufacturing.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.

Live IPO, GMP and market updates on Telegram

IPO open and close dates, grey market premium moves, subscription figures, allotment and listing days, and the market updates worth knowing about, posted on the channel as they happen.

Join the channel